Standout Papers

Nivolumab in metastatic urothelial carcinoma aft... 2008 2026 2014 2020 1.2k
  1. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial (2017)
    Padmanee Sharma, Margitta Retz et al. The Lancet Oncology
  2. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 (2008)
    Brian I. Rini, Susan Halabi et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 9 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

Renal Cell Carcinoma
2024 Standout
Renal cell carcinoma
2024 Standout
8 intermediate papers

Works of Daniel A. Vaena being referenced

Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
2019
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
2008 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Daniel A. Vaena 1169 1433 641 1086 67 2.7k
André P. Fay 1353 1252 604 740 112 2.4k
José Ángel Arranz 951 1513 399 1480 73 3.0k
Bradley A. McGregor 1344 1698 550 1117 168 3.0k
Thomas Powles 1051 2338 410 1872 103 3.5k
Jean Hoffman‐Censits 886 1179 340 2302 151 3.2k
Andrzej Kawecki 1350 1723 289 904 44 3.0k
Alessandra di Pietro 661 1033 281 592 95 1.8k
Yann Vano 1153 1369 526 276 81 2.3k
Jacqueline Vuky 658 1415 263 1375 64 2.5k
Marco Benasso 1608 1976 315 1206 67 3.6k

All Works

Loading papers...

Rankless by CCL
2026